<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:chebi fb="1" ids="36809">Tricyclic antidepressants</z:chebi> have been demonstrated in the laboratory to have anticancer properties </plain></SENT>
<SENT sid="1" pm="."><plain>A recent study by our group also suggested a protective effect against development of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> and <z:hpo ids='HP_0009733'>glioma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>This study aims to determine whether the anticancer action of tricyclics translates to improved survival in these <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> post-diagnosis </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: A study using the General Practice Research Database examined whether <z:chebi fb="1" ids="36809">tricyclic antidepressant</z:chebi> exposure in the months following diagnosis of <z:hpo ids='HP_0009733'>glioma</z:hpo> or <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> would affect longer term <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality </plain></SENT>
<SENT sid="4" pm="."><plain>Cox proportional hazards modelling adjusted for age, gender, smoking, body mass index, comorbidity, and diagnosed <z:hpo ids='HP_0000716'>depression</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: A cohort of 1,364 <z:hpo ids='HP_0009733'>glioma</z:hpo> and 16,519 colorectal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients were identified </plain></SENT>
<SENT sid="6" pm="."><plain>There was a non-significant reduction in the hazard for <z:hpo ids='HP_0009733'>glioma</z:hpo> patients treated with tricyclics (HR = 0.83, CI = 0.53-1.30) </plain></SENT>
<SENT sid="7" pm="."><plain>This was mainly found in patients who were not previously exposed to tricyclics (HR = 0.56, CI = 0.26-1.18) </plain></SENT>
<SENT sid="8" pm="."><plain>In contrast, a significant increase in hazard was found for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (HR = 1.37, CI = 1.21-1.54) </plain></SENT>
<SENT sid="9" pm="."><plain>This was mostly in patients prescribed low-dose tricyclics (HR = 1.57, CI = 1.33-1.86) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: We have shown no significant mortality reduction in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> or <z:hpo ids='HP_0009733'>glioma</z:hpo> patients treated with tricyclics </plain></SENT>
<SENT sid="11" pm="."><plain>An apparent detrimental effect observed in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> may be related to prescription of low-dose tricyclics in the management of pain related to <z:e sem="disease" ids="C0346957" disease_type="Neoplastic Process" abbrv="">disseminated cancer</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>We cannot rule out small effects or an effect that occurs exclusively at higher doses </plain></SENT>
<SENT sid="13" pm="."><plain>Blinded clinical studies may therefore be the only method of determining efficacy in <z:hpo ids='HP_0009733'>glioma</z:hpo> patients </plain></SENT>
</text></document>